Park et al. [37,38] found that MIP-3α induced airway hyperresponsiveness and bronchial airway remodeling, whereas MIP-3α inhibitors and monoclonal antibodies could reduce airway hyperresponsiveness, airway inflammation, and airway remodeling caused by MIP-3α [39]. This evidence concerns the gene CCL20 and airway hyperresponsiveness.